Bempedoic acid cuts limb events in PAD

Clinical takeaway: For patients with PAD who cannot tolerate adequate statin therapy, bempedoic acid is an oral LDL-C–lowering option with evidence suggesting meaningful reductions in both first and recurrent major adverse limb events.

Patients with PAD remain at high risk for limb-threatening ischemic events, and these findings suggest bempedoic acid may offer limb protection as well as cardiovascular benefit when guideline-recommended statin therapy cannot be tolerated.

In this analysis of the randomized CLEAR Outcomes trial, investigators evaluated limb outcomes among 1,624 participants with PAD at baseline. Participants in the parent trial received bempedoic acid 180 mg daily or placebo, and limb events were independently adjudicated by 2 blinded vascular specialists.

Over a median 41.1 months, 8.3% of placebo-treated patients experienced a first major adverse limb event (MALE), defined as worsening PAD requiring revascularization, chronic limb-threatening ischemia, or acute limb ischemia. Bempedoic acid reduced the risk of a first MALE by 36%, corresponding to a 2.5-percentage-point absolute reduction and a number needed to treat of 40.

The benefit was more pronounced when repeat events were included. The total MALE event rate in the placebo group was 13.7%, and bempedoic acid reduced first and recurrent events combined by 45%. Benefits were also directionally consistent when limb events were evaluated alongside major cardiovascular events.

The findings extend the cardiovascular benefits previously demonstrated with bempedoic acid to outcomes particularly important for patients with PAD. Because the limb analysis was exploratory and based on a PAD subgroup rather than a trial prospectively powered for MALE, the results warrant appropriate caution.

As the investigators concluded, the findings “support the early use of therapies with proven MALE benefit” to improve outcomes in PAD.

Source: Bonaca MP, et al. (2026 Aug 18) Circulation. Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial